Therapy News and Research

RSS

New breast cancer biomarker may help identify women's response to tamoxifen

Cancer researchers at the Kimmel Cancer Center at Jefferson and an international team of collaborators have discovered a biomarker in breast cancer that may help identify which women will respond to anti-estrogen therapy.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Cameron Health announces completion of $107 million equity financing round

Cameron Health, Inc., developer of the world's only completely subcutaneous implantable defibrillator, announced today that it has completed a $107 million equity financing round led by Alloy Ventures and Delphi Ventures.

18 May 2011

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.

18 May 2011

Clinical PET system for early stage breast cancer diagnosis

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

New book provides insight into new stem cell therapies for stabilizing heart function

A new book edited by researchers at Worcester Polytechnic Institute and the Stony Brook University School of Medicine provides a comprehensive look at the science and application of cellular therapies aimed at the leading cause of death---heart disease.

18 May 2011

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

The University of Washington Center for Commercialization and Pharmigene, a leader in advancing personalized medicine and reducing severe adverse reactions to drugs through genetic-based diagnostic solutions, today announced the execution of a licensing agreement between the parties.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Study finds three-month TB treatment regimen just as effective as standard longer course

"Health officials on Monday celebrated a faster treatment for people who have tuberculosis but aren't infectious, after investigators found a new combination of pills knocks out the disease in three months instead of nine," the Associated Press/Seattle Times reports.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Excaliber subsidiary merges with VistaGen

Excaliber Enterprises, Ltd. announced today that its wholly-owned subsidiary has merged with VistaGen Therapeutics, Inc., a private biotechnology company focused on stem cell-based drug rescue and drug development. As a result of the Merger, VistaGen is a wholly-owned subsidiary of Excaliber.

17 May 2011

CryoLife acquires Cardiogenesis

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that it has successfully completed its acquisition of Cardiogenesis Corporation.

17 May 2011

FDA grants 510(k) clearance to Asante's Pearl Insulin Pump

Asante Solutions, Inc., a medical device company focused on diabetes care, announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the company's Pearl Insulin Pump. Last month, the Pearl also received the CE Mark, a European proof of conformity that certifies the product meets EU safety, health and environmental requirements.

17 May 2011

New avenue for treating breast cancer

Researchers at the CHUM Research Centre and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

17 May 2011

Therapy News and Research

New breast cancer biomarker may help identify women's response to tamoxifen

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Cameron Health announces completion of $107 million equity financing round

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

Clinical PET system for early stage breast cancer diagnosis

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Aeterna Zentaris first quarter revenues increase to $7.4 million

New book provides insight into new stem cell therapies for stabilizing heart function

UW C4C, Pharmigene execute licensing agreement for warfarin personalized medicine technology

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Study finds three-month TB treatment regimen just as effective as standard longer course

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Excaliber subsidiary merges with VistaGen

CryoLife acquires Cardiogenesis

FDA grants 510(k) clearance to Asante's Pearl Insulin Pump

New avenue for treating breast cancer

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News